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Summary The tolerability and efficacy of four courses of paclitaxel and ifosfamide plus cisplatin every 3 weeks was evaluated in patients with
residual or refractory ovarian cancer. Additionally, supportive haematological effects of recombinant human interleukin 3 (rhlL-3) and
recombinant human granulocyte colony-stimulating factor (G-CSF) were studied. Paclitaxel starting dose was 135 mg m-2 (day 1), with
ifosfamide dose 1.2 g m-2 day-1 (days 2-4) and cisplatin dose 30 mg m-2 day-1 (days 2-4). All 16 patients received 5.0 9g kg-1 day-' G-CSF
(days 7-16) and, in addition, eight patients were randomized to receive 10 gg kg-' day-' rhlL-3 (days 5-9). Paclitaxel and ifosfamide doses
were reduced when grade IV haematological toxicity occurred. In the absence of grade IV haematological toxicity and normal recovery of
haematopoiesis, paclitaxel dose was escalated. Toxicity was evaluable in 56 courses, with haematological effects in 52. Despite antiemetic
treatment, nausea and vomiting (2 grade 1) occurred in 50 courses. Five patients had persisting peripheral neuropathy. Renal and liver
function were not affected. Grade IV neutropenia occurred in 12 out of 52 courses, with neutropenic fever in two patients, both of whom died
from fatal septicaemia. Grade IV thrombocytopenia without bleeding was observed in 15 courses. Grade IV haematological toxicity was
associated with hepatic metastases and concurrent increases in alkaline phosphatase (P <0.001) and gamma-glutamyltransferase
(P=0.007). No relation was found between haematological toxicity and pharmacokinetic parameters of paclitaxel. Patients treated with rhlL-3
showed a tendency to a faster platelet recovery (not affecting platelet nadir), and the cisplatin dose intensity was higher (P=0.025). Six of the
nine evaluable patients had a tumour response. The overall median progression-free survival was 7 months and the overall mean survival
was 13 months. In conclusion, this potentially interesting combination as second-line treatment showed a low tolerability with unexpected
mortality, while rhlL-3 administration tended to induce a more rapid platelet recovery.
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The prognosis of patients with advanced epithelial ovarian cancer
is poor and long-term survivors are scarce. This has urged the
continuous search for new therapies. In this respect, paclitaxel is
an interesting drug which has been added recently to the armamen-
tarium against ovarian cancer. It is non-cross-resistant with
cisplatin in vitro (Kelland and Abel, 1992) and in vivo (Gore et al.,
1995), and it has an unique mechanism of action by which cell
growth is inhibited.
Increased response rates after dose-intensified paclitaxel admin-
istration have been suggested by several phase I and II studies
(Eisenhauer et al, 1994; Kohn et al, 1994). Neutropenia is the most
frequent dose-limiting haematological toxicity after paclitaxel
(Trimble et al, 1993). Granulocyte colony-stimulating factor (G-
CSF) administration following paclitaxel results in reduction of
neutropenic episodes, including nadir depth, allowing increases in
paclitaxel dose (Sarosy et al, 1992; Kohn et al, 1994; Schiller et al,
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1994). Combination of paclitaxel with other effective chemo-
therapeutic drugs might be an alternative approach to improve
response rates. A rational step would be to combine paclitaxel with
cisplatin, the most active agent in ovarian cancer. In vitro, this
combination has demonstrated marked synergism (Untch et al,
1994) in a sequence-dependent way (Jekunen et al, 1994;
Vanhoefer et al, 1995). Recently, improved response rates, disease-
free survival and overall survival were demonstrated after pacli-
taxel and cisplatin combination therapy in first-line treatment for
ovarian cancer compared with cisplatin and cyclophoshamide
(McGuire et al, 1996).
We designed a feasibility study as second-line treatment for
patients with residual or relapsing ovarian cancer. Paclitaxel was
combined with cisplatin and ifosfamide, as the latter has demon-
strated activity in cisplatin-resistant ovarian cancer (Sutton et al,
1989; Markman et al, 1992). In order to reduce dose-limiting
neutropenia, all patients received recombinant methionyl human
granulocyte colony-stimulating factor (G-CSF). Thrombocyto-
penia, uncommon after paclitaxel alone, was expected because of
the addition of ifosfamide to the chemotherapeutic regimen.
Therefore, the effects of the addition ofrecombinant human inter-
leukin 3 (rhIL-3) were evaluated in a randomized way compared
with G-CSF alone. Preclinical (Bruno et al, 1988; Lu et al, 1988;
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Table 1 Drug adminstration schedule
Chemotherapy Dose Time Route Infusion time
(days) (h)
Drug (mg m-2 day-3)
Paclitaxel 135 1 i.v. 3
Ifosfamide 1200 2-4 i.v. 11/2
Cisplatin 30 2-4 i.v. 3
Haematopoietic growth factors (gg kg-' day-')
rhIL-3 (arm A) 10 5-9 s.c.
G-CSF (arm A and B) 5 7-16 s.c.
Teramura et al, 1988) and clinical studies (Biesma et al, 1992;
Postmus et al, 1992; Veldhuis et al, 1995) have demonstrated that
rhIL-3 is a stimulator ofthrombopoiesis. The combination ofrhIL-
3 and G-CSF acts synergistically in stimulating haematopoiesis in
vitro (Ottmann et al, 1989; Takaue et al, 1990). It is postulated that
rhIL-3 induced stimulation of immature non-committed haemato-
poietic cells results in increased numbers of more committed
haematopoietic cells responsive for G-CSF. Based on these
preclinical observations rhIL-3 was administered before G-CSF.
Paclitaxel pharmacokinetic assessment was performed in the last
seven patients after unpredictable haematological toxicity had
occurred.
In this paper, the tolerability, feasibility and efficacy of a novel
paclitaxel-based combination therapy is presented and, in addition,
the value of the addition ofrhIL-3 before G-CSF is described.
PATIENTS AND METHODS
All patients, aged 18-75 years, had histology-proven epithelial
ovarian carcinoma, had undergone appropriate surgical staging
and debulking, whenever possible, and had received first-line,
platinum-containing chemotherapy. Patients with residual disease
after or progressive disease during first-line chemotherapy and
patients with recurrences within 1 year after the last chemotherapy
regimen were eligible. A maximum of two prior chemotherapy
regimens was permitted, and patients had to have an evaluable
tumour. A leucocyte count of . 3 x 109 1-' and a platelet count of >
100 x 109 1-' were required at entry. Patients with severe heart,
lung, liver (serum bilirubin . 40 gmol 1-') or renal impairment
(creatinine clearance <60 ml min-') were excluded from the study,
as were patients with a WHO performance score grade III-IV and
those with atopy or any history of serious allergies.
Study design
Randomization was performed at entry between the combination
(arm A) ofG-CSF (Filgrastim, Amgen, Thousand Oaks, CA, USA)
and rhIL-3 (Sandoz, Basle, Switzerland) or G-CSF alone (arm B).
Chemotherapy consisted of paclitaxel (Bristol-Myers Squibb,
Regensburg, Germany), cisplatin (Bristol-Myers Squibb, Latina,
Italy) and ifosfamide (Asta Medica, Bielefeld, Germany). The
administration schedule of chemotherapy and haematopoietic
growth factors is shown in Table 1. All patients received dexam-
ethasone 20 mg orally (12 and 6 h before paclitaxel administration),
clemastine 2 mg and ranitidine 50 mg both i.v. 30 min before pacli-
taxel administration. Mesna was added, during and after ifosfamide,
in a dose equimolar to ifosfamide. To minimize cisplatin-induced
renal toxicity, a total of 5 1 of saline (0.9%) was administered daily
by i.v. infusion. Antiemetic prophylaxis consisted of three daily
doses ofondansetron (8 mg i.v.).
Chemotherapy was scheduled every 3 weeks and a total of four
courses were foreseen. The next chemotherapy course was post-
poned for up to a maximum of 4 weeks in circumstances of insuf-
ficient leucocyte (<3 x 1091-') orplatelet (<100 x 1091-1) recovery;
if this occurred, no paclitaxel escalation was allowed. The dose of
paclitaxel and ifosfamide was reduced ifpatients developed WHO
grade IV leucopenia with fever, which required antibiotic treat-
ment, and/or WHO grade IV thrombocytopenia with platelet trans-
fusions. Cisplatin and ifosfamide dose was reduced by 50% for
WHO grade II peripheral neurotoxicity, WHO grade I central
neurotoxicity and/or when the creatinine clearance dropped below
60 ml min-'. When more severe neurotoxicity occurred and/or the
creatinine clearance dropped below 40 ml min-', patients were
taken off study. Escalation of paclitaxel dose was allowed if, on
day 22, leucocytes were 2 3.0 x 1091-' and platelets > 100 x 1091-'
and if no grade IV haematological toxicity had occurred in the
preceding course.
The patients were monitored biweekly with physical examina-
tion and complete blood counts were obtained on days 1, 5, 9, 12,
15, 18 and 22 of a course. Blood chemical analyses were
performed on days 1 and 18 of each course. CA-125 levels were
obtained before, during and at the end of the fourth course. All
side-effects were scored according to WHO criteria. Patients were
taken off study if tumour progression was noted or if WHO grade
III to IV non-haematological toxicity was observed, excluding
nausea and vomiting.
The pharmacokinetic analysis (PK) of paclitaxel was initiated
during the study when grade IV haematological toxicity was
observed. PK sampling was performed in the last seven patients.
Blood samples were collected by i.v. sampling from the contralat-
eral infusion arm in EDTA tubes before, 1.5 h after start, at the end
of the paclitaxel infusion and at 6, 15,60 min and 2, 3,4, 8, 12,21,
30 and 48 h after the end of the infusion. Plasma samples were
obtained by immediate centrifugation and were analysed with high-
performance liquid chromatography as reported by Huizing et al
(1993). The plasma disappearance curves were modelled by using
the Kinfit computer software (MW/Pharm, Medi/ware, Groningen,
The Netherlands) as reported by Proost and Meijer (1992).
Tumour response was evaluated after two courses and at the end
of the study. Response criteria included the following: a clinical
complete response required the disappearance of all measurable
and evaluable disease (by non-invasive assessment), as well as
signs and symptoms related to the tumour, for longer than 4 weeks;
a partial response required a reduction of more than 50% in the
sum of the product of perpendicular diameters of all lesions,
lasting longer than 4 weeks; progressive disease was defined as an
increase of more than 50% in the sum of the product of perpendic-
ular diameters of all lesions; stable disease is any condition not
meeting the above response criteria. The study was approved by
the Medical Ethical Committee of the University Hospital,
Groningen. All patients gave informed consent.
Statistical analysis
To tests differences in blood counts between patients in arm A or
arm B, the Mann-Whitney U (Wilcoxon) test was used. The
Pearson chi-square test was used to discern differences in discrete
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Table 2 Patient characteristics and laboratory values at entry (median and
range)
Arm A (n=8) Arm B (n=8)
Age in years (range) 57.5 (24-65) 58 (31-63)
Performance score
0 6 7
1 2 1
FIGO stage
Ilc 1 2
Illa 1 1
Illb 0 1
IlIc 3 2
IV 3 2
Histology
Serous 5 3
Mucinous 3 4
Clear cell - 1
Prior CT
One regimen 7 7
Two regimens 1 1
Time since last CT (months) 4.5 (1-23) 4.5 (1-22)
Creatinine clearance (ml min-') 94 (90-180) 89 (70-121)
Serum creatinine (,umol 1-) 72 (57-83) 72 (60-93)
A, G-CSF + rhlL-3; B, G-CSF; CT, chemotherapy.
Table 3 Dose level and doses of paclitaxel (P), ifosfamide (I) and cisplatin
(C) in mg m-2 per course, with subsequent number of courses administered
Level Dose No. of courses administered
Arm A Arm B Total
P I C (n=27) (n=29) (n=56)
-3 0 1800 90 2 0 2
-2 75 2400 90 2 1 3
-1 100 3000 90 2 5 7
0 135 3600 90 8 13 21
1 150 3600 90 7 4 11
2 165 3600 90 4 4 8
3 175 3600 90 2 2 4
variables between both groups, and the Spearman rank analysis
was used for correlation coefficients. All P-values are two-sided,
only P-values <0.05 were considered significant. Median progres-
sion-free survival (PFS) and mean overall survival (OS) were
calculated with Kaplan-Meier survival analysis.
RESULTS
Sixteen patients were randomized, eight in each arm. The main
characteristics and laboratory values at entry are listed in Table 2.
Overall, the disease parameters, bone marrow, liver and renal func-
tion were equally balanced for both patient groups.
A total of 56 courses were evaluable for toxicity, 27 in arm A
and 29 in arm B (Table 2). Fifty-two courses, 27 in arm A and 25
in arm B, were available to evaluate haematological effects. The
median follow-up period was 12 months (range 9-16 months).
Table 4 Non-haematological toxicity per patient (no. of courses)
Arm A Arm B
Symptoms Patients (courses) Patients (courses)
Alopecia (grade III) 8 8
Facial erythema (all cycles) 8 8
Collapse 1 0
Nausea and vomiting
Grade 0 1 (4) 0
Grade 0 1 (4)
Grade II 1 (2) 1 (4)
Grade lIl 6 (21) 6 (19)
Peripheral neuropathy (during treatment)
Grade 0 4 5
Grade 4 (16) 3 (5)
Peripheral neuropathy (persistent)
GradeO 4 7
Grade 2 1
Grade II 2 0
Flu-like symptoms
Headache 5 (14) 1 (3)
Fever 0 0
Fatigue 5 (15) 4 (10)
Myalgia 0 2 (2)
Gastrointestinal symptoms
Mucositis 1 (1) 0
Oesophagitis 1 (1) 0
Abdominal pain 1 (1) 1 (1)
Diarrhoea 1 (1) 1 (1)
Constipation 1(1) 1 (1)
Intra-abdominal bleeding 0 1 (1)
Deep venous thrombosis 1 (1) 1 (1)
Death due to septicaemia and renal failure 1 1
Chemotherapy dose intensity
In Table 3, the doses of the combinations are listed for all courses.
The median interval between the courses was 3 weeks (range 3-5
weeks) for arm A and 4 weeks (range 3-5 weeks) for arm B
(P=0.03). The number of 3-week courses was 18 out of 26 (69%)
in arm A and 11 out of 25 (44%) in arm B, there were seven 4-
week courses in both arms, one 5-week course in arm A and seven
in arm B (P=0.046). The mean (± s.e.m.) delivered paclitaxel dose,
calculated per week, was 40 ± 3 mg m-2 in arm A and 34 ± 2 mg
m-2 in arm B. Ifosfamide dose per week was 1033 ± 52 mg m-2 for
arm A vs 940 ± 47 mg m-2 for arm B (not significant, NS). The
calculated weekly cisplatin dose was 27.5 ± 0.8 mg m-2 in arm A
and 24.5 ± 1.0 mg m-2 in arm B (P=0.025).
Toxicity
Five patients prematurely discontinued the study. Two patients
died during treatment, one in course 4, day 12 (arm B) and one in
course 1, day 10 (arm B). Both had proven neutropenic septi-
caemia, with hypotension and renal failure which had developed
acutely. Another patient experienced bleeding from a large liver
metastasis in the second course (arm B), two patients withdrew
their consent after 2 and 3 courses (both in arm A). One patient
switched from arm A to arm B after the first course, and the
remaining courses in this patient were therefore only evaluable for
toxicity. The major non-haematological toxic events are summa-
rized in Table 4. All patients experienced alopecia. One patient
collapsed during the first minutes of the first paclitaxel infusion
(arm A) and regained normal control spontaneously; the paclitaxel
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Figure 1 Mean (± s.e.m.) number of leucocytes in the first course for
patients receiving regimen A(E) or B (M)
was stopped and restarted at a slower infusion rate during the first
30 min of the paclitaxel infusion. One day after paclitaxel infu-
sion, facial erythema, which subsided within 2 days, was observed
in all patients. Nausea and vomiting requiring additional
antiemetic therapy (ondansetron, metoclopramide) was reported
by 12 patients and occurred in all courses. Three patients had tran-
sient nausea and vomiting and one patient experienced nausea
without vomiting. Nausea and vomiting had disappeared by day 9
ofeach course (as reported by the majority ofthe patients). Seven
patients complained of numbness and paraesthesias in fingers and
toes which disappeared before the next course (WHO grade I); in
four ofthese patients (arm A), the symptoms started after course 1.
These symptoms persisted and/or worsened in five patients after
course 4 (peripheral neuropathy WHO grade II). Two patients
experienced walking ataxia, lasting for more than 3 months. No
relation was found between the occurrence ofperipheral neurotox-
icity and the extent of prior treatment. Central neurotoxicity was
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Figure 3 Mean (± s.e.m.) number of platelets in the first course for patients
receiving regimen A (0) or B (U)
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Figure 2 Mean (± s.e.m.) number of neutrophils in the first course for
patients receiving regimen A (L) or B (M)
not observed at any time during the study. Headache was reported
by sixpatients,five from arm A andone from arm B. Other consti-
tutional symptoms were fatigue and myalgia which were consid-
ered mild to moderate. Headache and fatigue were most
pronounced during the days following chemotherapy administra-
tion, including the days rhIL-3 was administered.
Gastrointestinal symptoms were observed infrequently as
shown in Table 3 and were mild never exceeding WHO grade II.
One patient experienced an intra-abdominal bleeding from a large
hepatic metastasis, and chemotherapy was stopped after this
episode. Thebleeding started on day 3 ofthe second course; atthat
moment,the platelet count was 93 x 1091- and there were no signs
of clotting disorders. Deep venous thrombosis occurred in one
patient during rhIL-3 administration (day 9) in course 1 and rhIL-
3 was therefore discontinued and i.v. heparin and oral anticoagu-
lants were started. In the third course, again, deep venous
thrombosis was diagnosed, this time in the contralateral leg despite
optimal anticoagulant therapy. Physical examination and ultra-
sonography revealed no evidence of recurrent disease in the first
and second episode.
Haematology
As all patients received the same dose of chemotherapy in the
course 1, the haematological effects of rhIL-3 were analysed in
this course.
The mean number of leucocytes and neutrophils are shown in
Figure 1 and 2 respectively. The leucocyte nadir, observed day 9 in
both arms, was 3.7 ± 0.6 x 109 1-1 (mean±s.e.m.) for arm A and
2.9 ±0.8 x 109 1-1 for arm B. The neutrophil nadir was 2.2 ± 0.5
x 109 1-' and 2.4± 1.1 x 109 1-1 (mean±s.e.m.) and occurred day
9 in arm A and day 12 in arm B respectively (both NS). The
recovery of leucocytes and neutrophils tended to be faster for arm
A, but, as for the nadir, these differences were not statistically
significant. Grade IV leucopenia (<1 x 1091-1) occurred in 5 out of
27 courses for arm A (n=3, including neutropenic sepsis) and 5 out
of 25 courses in arm B (n=4, also including one sepsis). The
median duration ofgrade IV leucopenia to leucocytes >3 x 1091-1
was <6 days and was the same forboth arms. Grade IVneutropenia
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Table 5 Comparison of liver and renal function parameters (mean ± s.e.m.)
in courses with and without grade IV thrombocytopenia. Also shown are the
doses (mean ± s.e.m.) of chemotherapy administered in the respective
courses
Grade IV
thrombocytopenia
UNL No Yes P-value
AF (U -1) 120 89 ±5 126 ±7 <0.001
y-GT (U I-') 45 21 ±2 61 ± 12 0.007
AST(U1-1) 40 25±3 32±3 NS
ALT(U L1) 30 27±3 31 ±3 NS
Total bilirubin (gimol 1-1) 25.7 5 ± 0.5 7 ± 1 0.02
Creatinine (imol L-1) 106 67 ± 2 86 ±4 <0.001
Paclitaxel (mg m-2) 146 ±3 104± 11 0.001
Ifosfamide (mg m-2) 3582 ± 18 3032 ± 141 0.001
Cisplatin (mg m-2) 90 90 NS
UNL, upper normal limit.
(<500 x 1061-l) occurred in 7 out of27 courses in arm A (n=3) and
5 out of 25 courses in arm B (n=3). For lymphocytes, monocytes
and basophils, no differences between both arms were observed in
the first and subsequent courses. Eosinophils tended to be higher
(NS) on day 12, 15 and 18 forpatients treated with rhIL-3 (data not
shown). The platelet nadir in the first course was 77 ± 23 x 1091-'
(mean ± s.e.m.) in arm A and 80 ± 27 x 1091- in arm B (NS). This
nadir occurred on day 12 for arm A and day 15 for arm B (NS).
The recovery tended to be faster for arm A (Figure 3), however no
statistical significance was reached. Grade IV thrombocytopenia
(<25 x 109 1-') was observed in 9 out of 27 vs 6 out of 25 courses
for arm A and B respectively (NS). The number of prophylactic
platelet transfusions was similar in both arms, namely 9 out of 27
courses (n=3) in arm A versus 6 out of 25 courses (n=3) in arm B.
The median number of platelet transfusions required was respec-
tively 2 (range 1-5) and 1.5 (range 1-7) for arm A and B (NS). The
median time fromplatelets below 20 x 1091-1 to recoverto above 2
100 x 109 1-' was <3 days (range 3-6) for arm A and <4 days
(range 3-6) for arm B (NS).
Biochemistry
During the study, no changes were observed in liver and renal
function tests in individual patients. Courses with and without
grade IV leuco- and thrombocytopenia were compared with
respect to liver and renal function parameters (obtained on day 1 of
the involved course), i.e. AF, y-GT, AST, ALT, total bilirubin and
serum creatinine. The results ofthis analysis are shown in Table 5.
Serum levels of AF, y-GT,- total bilirubin and creatinine were
significantly higher for the courses in which grade IV leuco-
and/or thrombocytopenia was observed. These differences in renal
and liver function were not related to the previous chemotherapy
dose, as the dose administered was higher in courses in which no
grade IV leuco- and thrombocytopenia had occurred (Table 4). No
statistically significant differences with regard to these parameters
could be found at entry between patients who had experienced an
episode of grade IV leuco- and thrombocytopenia and those who
had not. However, all patients with liver metastases (n=4) devel-
oped grade IV haematological toxicity, whereas only 4 out of 12
patients without liver involvement developed haematological toxi-
city ofthis grade (NS).
Table 6 Pharmacokinetic (PK) parameters (n-7)
PK parameters Patient no.
1 2 3 4 5 6 7
Dpaci (mg m-2) 75 100 135 135 135 135 175
Cmax (mg 1-') 1.41 1.76 2.81 2.12 3.23 3.02 3.99
AUCO_.. (h mg-'I-') 5.37 5.27 7.57 7.72 10.18 11.08 12.25
t,, (a) (h) 0.50 0.16 0.71 0.54 0.74 0.62 0.73
t,I(f) (h) 12.16 6.84 16.35 8.39 7.71 8.05 12.82
dI(I h-1) 19.22 29.65 30.41 30.95 20.38 23.87 27.75
V. (l) 146.1 114.1 241.2 110.6 86.4 111.7 158.0
xO.1,M (h) 9.8 11.0 10.0 9.7 15.0 18.0 15.0
Abbreviations are defined in the text.
Pharmacokinetics
The PK parameters are listed in Table 6. Patients 1, 2 and 7
received a paclitaxel dose (Dpaci) of 75, 100 and 175 mg m-2,
respectively, and the remaining patients received a dose of 135 mg
m-2. Because of the known non-linearity of the pharmacokinetic
parameters (Huizing et al, 1993), no normalization was performed
and the data for the different doses are given. The maximum
concentration (Cmax) and the area under the curve (AUCO0,) were
correlated with the administered dose, correlation coefficient
(r)=0.91 (P=0.005) and r=0.87 (P=0.012) respectively. The
plasma concentration-time curve appeared to be biphasic with a
half-life of t,,2(a) ranging from 0.16 to 0.74 h and t,,2(1) ranging
from 6.84 to 16.35 h. The paclitaxel clearance (CI) range was
19.22-30.95 1 h-' and the steady state distribution volume (V s)
ranged from 86.4 to 241.2 1. The median time for which the pacli-
taxel concentration was above 0.1 gmol 1-1 (t,<O01) was 11.0 h
(range 9.7-18 h). No correlation could be found between the
various PK parameters, liver or renal function parameters and
haematological toxicity.
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Figure 4 Progression-free survival (PFS) and overall survival (OS) in all
patients
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Tumour response
Seven patients were not evaluable for tumour response as, in five
patients with microscopic disease at entry, no laparotomy was
performed after chemotherapy, and two patients died prematurely.
Of the remaining nine patients, three achieved stable disease (one
in arm A and two in arm B), three a partial response (all arm B)
and three patients were found to have a complete clinical response
(two in arm A and one in arm B). The total response rate in evalu-
able patients was therefore 67%. In 11 patients, CA-125 levels
were obtained; in two ofthese, the CA-125 level increased during
treatment, all the others demonstrated a decrease. In responders,
the mean CA-125 level decreased by 88% vs a 62% decrease in
non-responders (NS).
The mean PFS for responding, non-responding and non-evalu-
able patients was 7 months (95% confidence interval (CI) 6-8
months), 5 months (95% CI 3-6 months) and 8 months (95% CI
5-12 months) respectively (P=0.04, log rank). The median OS
was not reached during the follow-up of9-16 months, the average
OS of this group of patients was 13+ months (95% CI 10-15
months, Figure 4).
DISCUSSION
Short-lasting grade IV neutropenia after this combination therapy
was observed in 6 out of 16 patients (27%), a relatively low
frequency compared with otherreports such as those with reported
incidences above 50% after paclitaxel monotherapy (Einzig et al,
1992; Sarosy et al, 1992; Trimble et al, 1993; Thigpen et al, 1994).
After cisplatin-paclitaxel combination therapy, the incidence of
grade IV neutropenia was 78% (McGuire et al, 1996). Two out of
sixteen patients (12.5%) in our study, however, died during treat-
ment because of neutropenic septicaemia. This is a high mortality
compared with paclitaxel monotherapy (135 mg m-2, every 3
weeks) in which a 1.6% mortality was reported (Trimble et al,
1994). Remarkably, in our study no neutropenic fever, septicaemia
nor renal impairment was observed in the other patients. The
complication of severe bone marrow depression seems therefore
rather unpredictable. The tolerability of this regimen was
primarily determined by nausea, vomiting and neurotoxicity.
Grade III nausea and vomiting requiring additional antiemetic
therapy was quite substantial. Sensory neurotoxicity was observed
in 7 out of 16 patients (44%) and in five patients these symptoms
persisted after discontinuation ofthe chemotherapy, resulting in an
ataxic gait in two of them. A varying incidence of neurotoxicity
has been reported for paclitaxel (4-52%) (Eisenhauer et al, 1994;
Thigpen et al, 1994), for cisplatin (3-92%) (Cersosimo, 1989) and
for the combination of paclitaxel and cisplatin (27-28%)
(Rowinsky et al, 1991, McGuire et al, 1996). Both paclitaxel and
cisplatin induced neurotoxicity are cumulative and dose related
(Cersosimo, 1989; Sarosy et al, 1992; Eisenhauer et al, 1994).
Paclitaxel dose >250 mg m-2 is strongly associated with the occur-
rence of neurotoxicity, which is dose limiting at doses >300 mg
m-2 (Sarosy et al, 1992). Cisplatin-induced neurotoxicity is mainly
observed after cumulative doses of300 mg m-2 (Cersosimo, 1989).
Rowinsky et al (1991) found a 27% incidence of neurotoxicity
(n=44) for the combination of cisplatin and paclitaxel, compared
with 44% in our study. Their doses were 200 and 75 mg m-2, our
maximal doses were of 175 and 90 mg m-2 for paclitaxel and
cisplatin respectively. The frequency of persistent neurotoxicity
was higher in patients treated with rhIL-3 (NS). Direct effects of
rhIL-3 on the peripheral nerve system have not been reported. The
dose intensity ofcisplatin was somewhat higher in group A, which
may have affected the incidence ofneurotoxicity.
Deep venous thrombosis occurred twice in one patient. Afterthe
first event, rhIL-3 was discontinued. The symptoms, however,
recurred despite adequate anticoagulant therapy. Arterial throm-
bosis associated with rhIL-3 has been reported in the literature
(Theodossiou et al, 1994). No thromboembolic events were
reported by Trimble et al (1993) in their paper on approximately
1000 patients treated with paclitaxel only. However, recently
Sevelda et al (1994) reported thrombosis in three patients after
paclitaxel treatment. rhIL-3 related toxicity mainly consisted of
flu-like symptoms and was similar to otherclinical studies (Biesma
et al, 1992; Postmus et al, 1992; Biesma et al, 1993; D'Hondt et al,
1993; Veldhuis et al, 1995). The principal effects obtained with
rhIL-3 administration in this regimen are a shorter treatment
interval and a higher delivered cisplatin dose. There is a tendency
for a faster platelet recovery for patients treated with rhIL-3. This
did, however, not affect the incidence of grade IV thrombocy-
topenia and the number of platelet transfusions. Reduction of
chemotherapy-induced myelosuppression by rhIL-3 has been
observed earlier (D'Hondt et al, 1993; Veldhuis et al, 1995).
Grade IV leuco- and thrombocytopenia were related to the pres-
ence of hepatic metastases and increases in serum alpha fetopro-
tein (AF) and gamma-glutamyltransferase (y-GT). Whether these
increases in AF and y-GT affected paclitaxel metabolism and
excretion remains to be established, as no correlation could be
found with PK parameters. However, the number ofpatients in our
study was probably too small to discriminate. Others have
suggested that increases in AF and y-GT may affect metabolism
and excretion ofpaclitaxel (Huizing et al, 1995).
A tumour response was observed in six out of nine evaluable
patients. Response rates of larger monotherapy paclitaxel studies
varied between 16% and 48% (Einzig et al, 1992; Eisenhauer et al,
1994; Kohn et al, 1994; Pearl et al, 1994; Thigpen et al, 1994).
Median progression-free survival and overall survival were in line
with data obtained after paclitaxel monotherapy (Einzig et al,
1992; Eisenhauer et al, 1994; Kohn et al, 1994; Pearl et al, 1994;
Thigpen et al, 1994).
In this small feasibility study, the combination ofpaclitaxel with
cisplatin and ifosfamide resulted in a relatively high response rate
for a second-line regimen in refractory patients. Toxicity was,
however, substantial and therefore this regimen should not be
promoted for patients with advanced and platinum-refractory
ovarian cancer. As the principal aim of this study was to obtain
data on tolerability and efficacy, no cost-benefit analysis was
performed.
rhIL-3-related effects revealed a tendency to a higher platelet
nadir count and faster platelet recovery. The presence of hepatic
metastases and decreased liver excretory function, as indicated by
increased cholestatic parameters, may enhance the incidence of
grade IV haematopoietic toxicity because of decreased excretion
of paclitaxel and ifosfamide, this should be taken into account
when selecting patients for paclitaxel combination treatment.
REFERENCES
Biesma B, Willemse PHB, Mulder NH, Sleijfer DTh, Gietema JA, Mull R, Limburg
PC, Bouma J, Vellenga E and de Vries EGE (1992) Effects of interleukin-3
after chemotherapy for advanced ovarian cancer. Blood 80: 1141-1148
British Journal ofCancer (1997) 75(5), 703-709 0 CancerResearch Campaign 1997Paclitaxel-containing therapyandgrowth factors in ovarian cancer 709
Biesma B, Pokorny R, Kovarik JM, Duffy FA, Willemse PHB, Mulder NH and de
Vries EGE (1993) Pharmacokinetics ofrecombinant human interleukin 3
administered subcutaneously and by continuous intravenous infusion in
patients after chemotherapy for ovarian cancer. Cancer Res 53: 5915-5919
Bruno E, Briddell R and Hoffmanm R (1988) Effect ofrecombinant and purified
hematopoietic growth factors on human megakaryocyte formation. Exp
Hematol 70: 371-377
Cersosimo RJ (1989) Cisplatin neurotoxicity. Cancer Treat Rev 16: 195-21 1
D'Hondt V, Weynants P, Humblet Y, Guilaume T, Canon J-L, Beauduin M, Duprez
P, Longueville J, Mull R, Chatelain C and Symann M (1993) Dose-dependent
interleukin-3 stimulation ofthrombopoiesis and neutropoiesis in patients with
small-cell lung carcinoma before and following chemotherapy: a placebo-
controlled randomized phase Ib study. J Clin Oncol 11: 2063-2071
Einzig Al, Wiernik PH, SasloffJ, Runowicz CD and Goldberg GL (1992) Phase II
study and long-term follow-up ofpatients treated with taxol for advanced
ovarian adenocarcinoma. J Clin Oncol 10: 1748-1753
Eisenhauer EA, Ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van
der Burg MEL, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M,
Santabarbara P, Onetto M, Winograd B and Canetta R (1994)
European-Canadian randomized trial ofpaclitaxel in relapsed ovarian cancer:
high-dose versus low-dose and long versus short infusion. J Clin Oncol 12:
2654-2666
Gore ME, Preston N, A'Hem RP, Hill C, Mitchell P, Chang J and Nicolson M (1995)
Platinum-taxol non-cross resistance in epithelial ovarian cancer. Br J Cancer
71: 1308-1310
Huizing MT, Keung ACF, Rosing H, van der Kuij V, ten Bokkel Huinink WW,
Mandjes IM, Dubbelman AC, Pinedo HM and Beijnen JH (1993)
Pharmacokinetics ofpaclitaxel and metabolites in a randomized comparative
study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:
2127-2135
Huizing MT, Vermorken JB, Rosing H, ten Bokkel Huinink WW, Mandjes I,
Winograd, Pinedo HM and Beijnen JH (1995) Pharmacology ofpaclitaxel and
three main metabolites in patients with advanced breast carcinoma refractory to
anthracycline therapy treated with a 3 hour paclitaxel infusion: a European
Cancer Center (ECC) trial. Ann Oncol 6: 699-704
Jekunen AP, Christen RD, Shalinsky DR and Howell SB (1994) Synergistic
interaction between cisplatin and taxol in human ovarian cancer cells in vitro.
Br J Cancer 64: 299-236
Kelland LR and Abel G (1992) Comparative in vitro cytotoxicity oftaxol and
taxotere against cisplatin-senstive and -resistent human ovarian carcinoma cell
lines. Cancer Chemother Pharmacol 30: 444-450
Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg SM, Rothenberg M,
Adamo DO, Davis P, Ognibene FP, Cunnion RE and Reed E (1994) Dose-
intense taxol: high response rate in patients with platinum resistant recurrent
ovarian cancer. JNatl Cancer Inst 86: 18-24
Lu L, Briddell RA, Graham CD, Brandt JE, Bruno E and Hoffman R (1988) Effect
of recombinant and purified human haematopoietic growth factors on in vitro
colony formation by enriched populations human megakaryocyte progenitor
cells. Br J Haematol 70: 149-156
Markman M, Hakes Th, Reichman B, Lewis JL, Rubin S, Jones W, Almadrones L,
Pizzuto S and Hoskins W (1992) Ifosfamide and mesna in previously treated
advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin
Oncol 10: 243-248
McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Arstrong
DK and Donehower RC (1989) Taxol: a unique antineoplastic agent with
significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med
111: 273-279
McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Arstrong
DK and Donehower RC (1989) Taxol: a unique antineoplastic agent with
significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med
111: 273-279
McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clark-
Pearson DL and Davidson M (1996) Cyclophosphamide and cisplatin
compared with paclitaxel and cisplatin in patients with stage III and stage IV
ovarian cancer. NEnglJ Med334: 1-6
Ottmann OG, Abboud M, Welte K, Souza LM and Pelus LM (1989) Stimulation of
human hematopoietic progenitor cell proliferation and differentiation by
recombinant human interleukin 3. Comparison and interactions with
recombinant human granulocyte-macrophage and granulocyte colony-
stimulating factors. Exp Hematol 17: 191-197
Postmus PE, Gietema JA, Damsma 0, Biesma B, Limburg PC, Vellenga E and de
Vries EGE (1992) Effects ofrecombinant human interleukin-3 in patients with
relapsed small-cell lung cancer treated with chemotherapy: a dose finding
study. J Clin Oncol 10: 1131-1140
Proost JH and Meijer DKF (1992) MW/PHARM, an integrated software package for
drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol
Med 22: 155-163
Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere EA,
Ettinger DS, Lubejko BG, Clark B, Sartorius SE, Comblath DR, Hendricks CB
and Donehower RC (1991) Sequences oftaxol and cisplatin: a phase I and
pharmacologic study. J Clin Oncol 9: 1692-1703
Sarosy G, Kohn E, Stone DA, Rothenberg M, Jacob J, Adamo DO, Ognibene FP,
Cunnion RE and Reed E (1992) Phase I study oftaxol and granulocyte colony-
stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10:
1165-1170
Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C and
Spriggs D (1994) Phase I trial of 3-hour infusion ofpaclitaxel with or without
granulocyte colony-stimulating factor in patients with advanced cancer. J Clin
Oncol 12: 241-248
Sevelda P, Mayerhofer K, Obermair A, Stolzlechner J and Kurz C (1994)
Thrombosis with paclitaxel. Lancet 343: 727-728
Sutton GP, Blessing JA, Homesly HD, Berman ML and Malfetano J (1989) Phase II
trial ofifosfamide and mesna in advanced ovarian carcinoma: a gynecologic
oncology group study. J Clin Oncol 7: 1672-1676
Takaue Y, Kawano Y, Reading CL, Watanabe T, Abe T, Ninomiya T, Shimizu E,
Ogura T, Kuroda Y, Yokobayashi A, Nakahata T, Asano S and Ventura G
(1990) Effects of recombinant human G-CSF, GM-CSF, IL-3, and IL- la on the
growth ofpurified human peripheral blood progenitors. Blood 76: 330-335
Teramura M, Katahira J, Hoshino S, Motoji T, Oshimi K and Mizoguchi H (1988)
Clonal growth ofhuman megakaryocyte progenitors in serum-free cultures:
effect ofrecombinant human interleukin 3. Exp Hematol 16: 843-848
Theodossiou C, Kroog G, Ettinghausen S, Tolcher A, Cowan K and O'Shaughnessy
J (1994) Acute arterial thrombosis in a patient with breast cancer after
chemotherapy with 5-fluorouracil, doxorubicin, leucovorin, cyclophosphamide,
and interleukin-3. Cancer 74: 2808-2810
Thigpen JT, Blessing JA, Ball H, Hummel SJ and Barrett RJ (1994) Phase II trial of
paclitaxel in patients with progressive ovarian carcinoma after platinum-based
chemotherapy: a gynecologic oncology group study. J Clin Oncol 12:
1748-1753
Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS,
Christina MC, Canetta R, Onetto M, Hayn R and Arbuck SG (1993) Paclitaxel
for platinum-refractory ovarian cancer: results from the first 1,000 patients
registered to National Cancer Institute Treatment Referal Center 9103. J Clin
Oncol 11: 2405-2410
Untch M, Sevin B-U, Perras JP, Angioli R, Untch A, Hightower RD, Koechli 0 and
Averette HE (1994) Evaluation ofpaclitaxel (taxol), cisplatin, and the
combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell
viability assay. Gynecol Oncol 53: 44-49
Vanhoefer U, Harstrick A, Wilke H, Schleucher N, Walles H, Schroder J and
Seeber S (1995) Schedule-dependent antagonism ofpaclitaxel and cisplatin in
human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer 31A:
92-97
Veldhuis GJ, Willemse PHB, van Gameren MM, Aalders JG, Mulder NH, Mull R,
Biesma B and de Vries EGE (1995) Recombinant human interleukin-3 to dose-
intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian
cancer: a phase I trial. J Clin Oncol 13: 733-740
C Cancer Research Campaign 1997 British Journal ofCancer(1997) 75(5), 703-709